High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.
This policy brief is part of a series of recommendations from the Baker Institute for the incoming president’s administration.
Jan. 20, 2017, 5:55 p.m.
Ana S. Iltis, Ph.D., is a nonresident scholar in the Center for Health and Biosciences. She is the director of the Center for Bioethics, Health and Society and professor of philosophy at Wake Forest University. Iltis also holds an appointment …
Daniel S. Wagner, Ph.D., is an associate professor of biochemistry and cell biology at Rice University and a Rice faculty scholar at the Baker Institute. He studies developmental biology and investigates the genetic regulation of early development in the zebrafish. …
September 09, 2022
Advances in biomedical research are often hailed for their potential in treating a variety of …
September 17, 2022
The Texas Collaborative Center for Hepatocellular Cancer (TeCH) at Baylor College of Medicine will host …
October 14, 2022
Vaccines are one of the most effective ways to reduce the spread of disease and …
